PURPOSE: To identify and understand isomerization products and degradation profile of different aspartate residues in an IgG1 monoclonal antibody. METHODS: Recombinant IgG1 was incubated for extended periods of time in a formulation buffer at recommended and accelerated storage temperatures. Isomerization reaction products were analyzed using ion exchange chromatography (IEC), hydrophobic interaction chromatography (HIC), peptide mapping, and LC-MS. Model peptides with sequences containing specific aspartate residues in IgG1 were synthesized and incubated under accelerated conditions. Products of isomerization reactions of peptides were analyzed by reverse phase chromatography (RP-HPLC) and LC-MS. X-ray crystallography data from Fab of IgG1 were used to understand mechanism of isomerization reactions. RESULTS: A MAb containing labile Asp32-Gly sequence in CDR I region undergoes rapid isomerization reaction and leads to formation of isoaspartate (IsoAsp) and cyclic imide (Asu) forms. Isomerization of aspartate residues was observed in a non-CDR region containing Asp74-Ser sequence. Isomerization reaction at Asp74-Ser led to formation of Asu74 and trace isoAsp74. While isoAsp32 increased linearly with time, isoAsp74 did not increase during storage. Asu32 and Asu74 followed non-linear degradation kinetics and reached steady state over time. Isomerization reaction of two different model peptides containing Asp32-Gly or Asp74-Ser with neighboring amino acid sequences as those found in the MAb result in formation of IsoAsp. CONCLUSIONS: Observed levels of Asu and trace IsoAsp at the Asp74 site are unusual for typical isomerization reactions. In addition to primary sequences, pKa, solvent exposure and high order structure around aspartate residues may have influenced isomerization reaction at Asp74 in MAbI. Different degradation profiles from the two Asp residues can influence shelf life and should be carefully evaluated during product development.
PURPOSE: To identify and understand isomerization products and degradation profile of different aspartate residues in an IgG1 monoclonal antibody. METHODS: Recombinant IgG1 was incubated for extended periods of time in a formulation buffer at recommended and accelerated storage temperatures. Isomerization reaction products were analyzed using ion exchange chromatography (IEC), hydrophobic interaction chromatography (HIC), peptide mapping, and LC-MS. Model peptides with sequences containing specific aspartate residues in IgG1 were synthesized and incubated under accelerated conditions. Products of isomerization reactions of peptides were analyzed by reverse phase chromatography (RP-HPLC) and LC-MS. X-ray crystallography data from Fab of IgG1 were used to understand mechanism of isomerization reactions. RESULTS: A MAb containing labile Asp32-Gly sequence in CDR I region undergoes rapid isomerization reaction and leads to formation of isoaspartate (IsoAsp) and cyclic imide (Asu) forms. Isomerization of aspartate residues was observed in a non-CDR region containing Asp74-Ser sequence. Isomerization reaction at Asp74-Ser led to formation of Asu74 and trace isoAsp74. While isoAsp32 increased linearly with time, isoAsp74 did not increase during storage. Asu32 and Asu74 followed non-linear degradation kinetics and reached steady state over time. Isomerization reaction of two different model peptides containing Asp32-Gly or Asp74-Ser with neighboring amino acid sequences as those found in the MAb result in formation of IsoAsp. CONCLUSIONS: Observed levels of Asu and trace IsoAsp at the Asp74 site are unusual for typical isomerization reactions. In addition to primary sequences, pKa, solvent exposure and high order structure around aspartate residues may have influenced isomerization reaction at Asp74 in MAbI. Different degradation profiles from the two Asp residues can influence shelf life and should be carefully evaluated during product development.
Authors: R J Harris; B Kabakoff; F D Macchi; F J Shen; M Kwong; J D Andya; S J Shire; N Bjork; K Totpal; A B Chen Journal: J Chromatogr B Biomed Sci Appl Date: 2001-03-10
Authors: Grace C Chu; Dirk Chelius; Gang Xiao; Hui K Khor; Sururat Coulibaly; Pavel V Bondarenko Journal: Pharm Res Date: 2007-03-24 Impact factor: 4.580
Authors: Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu Journal: MAbs Date: 2018-12-17 Impact factor: 5.857
Authors: Markus Haberger; Katrin Bomans; Katharina Diepold; Michaela Hook; Jana Gassner; Tilman Schlothauer; Adrian Zwick; Christian Spick; Jochen Felix Kepert; Brigitte Hienz; Michael Wiedmann; Hermann Beck; Philipp Metzger; Michael Mølhøj; Constanze Knoblich; Ulla Grauschopf; Dietmar Reusch; Patrick Bulau Journal: MAbs Date: 2014-01-17 Impact factor: 5.857
Authors: Jasmin F Sydow; Florian Lipsmeier; Vincent Larraillet; Maximiliane Hilger; Bjoern Mautz; Michael Mølhøj; Jan Kuentzer; Stefan Klostermann; Juergen Schoch; Hans R Voelger; Joerg T Regula; Patrick Cramer; Apollon Papadimitriou; Hubert Kettenberger Journal: PLoS One Date: 2014-06-24 Impact factor: 3.240
Authors: Wenkui Lan; Joseph J Valente; Andrew Ilott; Naresh Chennamsetty; Zhihua Liu; Joseph M Rizzo; Aaron P Yamniuk; Difei Qiu; Holly M Shackman; Mark S Bolgar Journal: MAbs Date: 2020 Jan-Dec Impact factor: 5.857